Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Annovis Bio (ANVS) is described as technically oversold, signaling that heavy selling pressure may be nearing exhaustion. Upward revisions to earnings estimates by Wall Street analysts reinforce the case for a potential near-term trend reversal. The development is a positive technical and estimate-revision signal for ANVS, though no specific earnings-revision magnitude or price target was provided.